Cargando…

Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion

The aim of this study was to evaluate the efficacy of a treat-and-extend (T&E) regimen of ranibizumab as the first-choice treatment in macular oedema (MO) secondary to branch retinal vein occlusion (BRVO). We conducted a retrospective study of 20 patients who developed MO due to BRVO treated wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez-Fernández, Carmen Antía, Campo-Gesto, Ana, López-López, Aida, Gayoso-Rey, Mónica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778817/
https://www.ncbi.nlm.nih.gov/pubmed/35056116
http://dx.doi.org/10.3390/ph15010059
_version_ 1784637416163770368
author Rodríguez-Fernández, Carmen Antía
Campo-Gesto, Ana
López-López, Aida
Gayoso-Rey, Mónica
author_facet Rodríguez-Fernández, Carmen Antía
Campo-Gesto, Ana
López-López, Aida
Gayoso-Rey, Mónica
author_sort Rodríguez-Fernández, Carmen Antía
collection PubMed
description The aim of this study was to evaluate the efficacy of a treat-and-extend (T&E) regimen of ranibizumab as the first-choice treatment in macular oedema (MO) secondary to branch retinal vein occlusion (BRVO). We conducted a retrospective study of 20 patients who developed MO due to BRVO treated with intravitreal ranibizumab in a T&E regimen between 2016 and 2017 with a minimum follow-up of two years. Patients were classified as complete responders if treated with ranibizumab alone or incomplete responders if salvage treatment with other medications or laser was needed. Data on best corrected visual acuity (BCVA) and central macular thickness (CMT) every 6 months were recorded. The mean BCVA (logMAR) improved from 0.60 ± 0.36 to 0.29 ± 0.44 and the CMT decreased from 559.85 ± 198.61 to 305.85 ± 11.78 μm. We found statistically significant differences between complete and incomplete responders on the average number of injections during the second year (2.46 ± 2.18 compared to 5.43 ± 1.27; p = 0.007) and change of the BCVA and CMT between both groups (p < 0.001) at 6, 12, 18 and 24 months. T&E seems to be effective in MO secondary to BRVO, improving visual function and decreasing CMT, with less need for injections.
format Online
Article
Text
id pubmed-8778817
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87788172022-01-22 Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion Rodríguez-Fernández, Carmen Antía Campo-Gesto, Ana López-López, Aida Gayoso-Rey, Mónica Pharmaceuticals (Basel) Article The aim of this study was to evaluate the efficacy of a treat-and-extend (T&E) regimen of ranibizumab as the first-choice treatment in macular oedema (MO) secondary to branch retinal vein occlusion (BRVO). We conducted a retrospective study of 20 patients who developed MO due to BRVO treated with intravitreal ranibizumab in a T&E regimen between 2016 and 2017 with a minimum follow-up of two years. Patients were classified as complete responders if treated with ranibizumab alone or incomplete responders if salvage treatment with other medications or laser was needed. Data on best corrected visual acuity (BCVA) and central macular thickness (CMT) every 6 months were recorded. The mean BCVA (logMAR) improved from 0.60 ± 0.36 to 0.29 ± 0.44 and the CMT decreased from 559.85 ± 198.61 to 305.85 ± 11.78 μm. We found statistically significant differences between complete and incomplete responders on the average number of injections during the second year (2.46 ± 2.18 compared to 5.43 ± 1.27; p = 0.007) and change of the BCVA and CMT between both groups (p < 0.001) at 6, 12, 18 and 24 months. T&E seems to be effective in MO secondary to BRVO, improving visual function and decreasing CMT, with less need for injections. MDPI 2022-01-03 /pmc/articles/PMC8778817/ /pubmed/35056116 http://dx.doi.org/10.3390/ph15010059 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rodríguez-Fernández, Carmen Antía
Campo-Gesto, Ana
López-López, Aida
Gayoso-Rey, Mónica
Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
title Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
title_full Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
title_fullStr Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
title_full_unstemmed Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
title_short Real-World Evidence for Treat-and-Extend Regimen of Ranibizumab Therapy for Macular Oedema Secondary to Branch Retinal Vein Occlusion
title_sort real-world evidence for treat-and-extend regimen of ranibizumab therapy for macular oedema secondary to branch retinal vein occlusion
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778817/
https://www.ncbi.nlm.nih.gov/pubmed/35056116
http://dx.doi.org/10.3390/ph15010059
work_keys_str_mv AT rodriguezfernandezcarmenantia realworldevidencefortreatandextendregimenofranibizumabtherapyformacularoedemasecondarytobranchretinalveinocclusion
AT campogestoana realworldevidencefortreatandextendregimenofranibizumabtherapyformacularoedemasecondarytobranchretinalveinocclusion
AT lopezlopezaida realworldevidencefortreatandextendregimenofranibizumabtherapyformacularoedemasecondarytobranchretinalveinocclusion
AT gayosoreymonica realworldevidencefortreatandextendregimenofranibizumabtherapyformacularoedemasecondarytobranchretinalveinocclusion